Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: Despite research efforts to develop more effective diagnostic and therapeutic approaches, malignant pleural mesothelioma (MPM) prognosis remains poor. The assessment of tumor response to therapy can be improved by a deeper phenotypical classification of the tumor, with emphasis on its clinico-biological heterogeneity. The identification of molecular profiles is a powerful approach to better define MPM subclasses and targeted therapies. Experimental Design: Molecular subclasses were defined by transcriptomic microarray on 38 primary MPM cultures. A three-gene predictor, identified by quantitative reverse transcription PCR, was used to classify an independent series of 108 frozen tumor samples. Gene mutations were determined in BAP1, CDKN2A, CDKN2B, NF2, and TP53. Epithelial-to-mesenchymal transition (EMT) markers were studied at the mRNA and protein levels. Results: Unsupervised hierarchical clustering on transcriptomic data defined two robust MPM subgroups (C1 and C2), closely related to prognosis and partly to histologic subtypes. All sarcomatoid/desmoplastic MPM were included in the C2 subgroup. Epithelioid MPM were found in both subgroups, with a worse survival prognosis in the C2 subgroup. This classification and its association with histologic subtypes and survival were validated in our independent series using the three-gene predictor. Similar subgroups were found after classification of other MPM series from transcriptomic public datasets. C1 subgroup exhibited more frequent BAP1 alterations. Pathway analysis revealed that EMT was differentially regulated between MPM subgroups. C2 subgroup is characterized by a mesenchymal phenotype. Conclusions: A robust classification of MPM that defines two subgroups of epithelioid MPM, characterized by different molecular profiles, gene alterations, and survival outcomes, was established. Clin Cancer Res; 20(5); 1323–34. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299 · cited 1×
“To further characterize the EMT in C1 and C2 subgroups, several sources of positive and negative EMT markers described in relevant publications were assembled (32-34) (list given in Supplementary Table S2).”
BackgroundTargeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · cited 1×
“Specific TGF-beta signaling inhibitors have been developed (57) and may be valuable drugs for targeted therapy of the C2 subgroup MPM.”
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Huang, S. X. L., Jaurand, M.-C., Kamp, D. W., Whysner, J., & Hei, T. K. (2011) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2011.556051 · Cited by 163 · cited 1×
“Its major risk factor is past exposure to asbestos fibers (1).”
BackgroundSelf-citation
Cited by
Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
Self-citationEMT and inflammation: inseparable actors of cancer progression
Suarez‐Carmona, M., Lesage, J., Cataldo, D., & Gilles, C. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12095 · Cited by 566
Cigognetti, M., Lonardi, S., Fisogni, S., Balzarini, P., Pellegrini, V., Tironi, A., Bercich, L., Bugatti, M., Rossi, G., Murer, B., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.65 · Cited by 306
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144
Metadata
- Authors
- de Reyniès, A., Jaurand, M.-C., Renier, A., Couchy, G., Hysi, I., Elarouci, N., Galateau-Sallé, F., Copin, M.-C., Hofman, P., Cazes, A., Andujar, P., Imbeaud, S., Petel, F., Pairon, J.-C., Le Pimpec-Barthes, F., Zucman-Rossi, J., & Jean, D.
- Venue
- Clinical Cancer Research
- Published
- 2014-03-01
- Volume
- 20
- Issue
- 5
- Pages
- 1323-1334
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2118880233
- Cited by
- 148
- References
- 5
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2429
- The paper
- de Reyniès, A., Jaurand, M.-C., Renier, A., Couchy, G., Hysi, I., Elarouci, N., Galateau-Sallé, F., Copin, M.-C., Hofman, P., Cazes, A., Andujar, P., Imbeaud, S., Petel, F., Pairon, J.-C., Le Pimpec-Barthes, F., Zucman-Rossi, J., & Jean, D. (2014). Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.